Pleiotropic Roles of SIRTs in Tumor Cell Metabolism

Overview

The sirtuin family (SIRT1–SIRT7) are NAD+-dependent acyltransferases whose pleiotropy in tumor metabolism stems from three sources: (1) subcellular compartmentalization — nuclear SIRT1/SIRT6/SIRT7, cytosolic SIRT2, and mitochondrial SIRT3/SIRT4/SIRT5 act on distinct metabolic nodes; (2) catalytic promiscuity — deacetylation, demalonylation, desuccinylation, deglutarylation, and ADP-ribosylation; and (3) context-dependence — the same sirtuin can be tumor-suppressive or oncogenic depending on tumor type, stage, and genetic background.

Metabolic axes

Glycolysis & the Warburg Effect

• SIRT6 is the clearest anti-Warburg sirtuin: it corepresses HIF-1α and suppresses transcription of glycolytic enzymes (glucose transporters, Hexokinase 2) and deacetylates histone H3 at the ERK1/2 promoters. Loss of SIRT6 permits "Warburg-like" aerobic glycolysis; its restoration suppresses glycolysis in HCC/glioma (via JAK2/STAT3) and enhances radiosensitivity in Lung Cancer.
• SIRT3 opposes aerobic glycolysis indirectly through redox: it activates MnSOD/SOD2 and IDH2, lowering ROS, which destabilizes HIF-1α — cutting the master glycolytic transcription factor. SIRT3 loss thus skews toward the Warburg Effect.
• SIRT1 is bidirectional: deacetylation of PGC-1α represses glycolysis and drives oxidative phosphorylation, yet SIRT1 also partners with oncogenic c-Myc and HIF-1α in some contexts (e.g., heterozygous deletion in CRC induces c-Myc → glutamine metabolism → proliferation).
• SIRT2 promotes tumor glycolysis in some settings by deacetylating phosphoglycerate mutase at Lys100 → channeling into NADPH production and accelerated tumor growth in Lung Cancer.
• SIRT5 is protumorigenic in CRC, HCC, and NSCLC by reprogramming metabolism toward glycolysis and glutaminolysis.

Glutamine metabolism & TCA anaplerosis

• SIRT4 is the clearest anti-glutamine node: it mono-ADP-ribosylates GDH, limiting glutamate→α-ketoglutarate flux and restricting the anaplerotic carbon supply to the TCA cycle that "glutamine-addicted" cancers depend on. Loss of SIRT4 is common in HCC, gastric, CRC, bladder, and breast cancer and predicts poor prognosis — making it a metabolic tumor suppressor.
• SIRT5 does the opposite: in CRC it enhances glutaminolysis and desuccinylates LDHB to hyperactivate autophagy, feeding cancer cells recycled nutrients.
• SIRT3 couples into this circuit by stimulating pyruvate dehydrogenase complex (PDC) and activating AceCS2, favoring oxidative TCA flux and suppressing the glycolytic program.
• The NAD+/TCA link matters broadly: MYC-high tumors sustain a glutamine-fueled TCA cycle via Complex I-regenerated NAD+, and sirtuins are the NAD+-sensitive brake on these same pathways.

ROS, redox, and lipid metabolism

• SIRT3 and SIRT5 coordinate antioxidant defense (SOD2/SOD1, IDH2, NADPH recycling); SIRT3 lowers mitochondrial membrane potential and ROS, protecting genomic integrity (ATM–Chk2) but also conferring radioresistance.
• SIRT6 suppresses de novo lipogenesis by deacetylating H3 at the SREBP promoter to inhibit SREBP1/2 and ChREBP.
• SIRT1 activates cytoplasmic AceCS1 (fatty acid synthesis) and regulates PPAR-γ, while SIRT4 suppresses hepatic fatty acid oxidation (MTPα) and promotes lipid accumulation under nutrient-replete conditions.